|
BIIB's Revenue Growth by Quarter and Year
Biogen Inc 's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| BIIB Revenue (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
| IV Quarter |
December |
-
|
2,733.80
|
2,852.60
|
3,671.30
|
| III Quarter |
September |
-
|
2,778.90
|
3,376.10
|
3,600.10
|
| II Quarter |
June |
-
|
2,775.00
|
3,681.60
|
3,616.70
|
| I Quarter |
March |
2,531.80
|
2,694.00
|
3,534.30
|
3,489.80
|
| FY |
|
2,531.80
|
10,981.70
|
13,444.60
|
14,377.90
|
| BIIB Revenue first quarter 2022 Y/Y Growth Comment |
Biogen Inc reported decrease in Revenue in the first quarter 2022 by -6.02% to $ 2,531.80 millions, from the same quarter in 2021.
The decrease in the first quarter 2022 Biogen Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 2.41%.
Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue decline of -6.02% ranks overall at the positon no. 766 in the first quarter 2022.
|
| BIIB Revenue ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
-4.16 % |
-22.3 % |
4.11 % |
| III Quarter |
September |
- |
-17.69 % |
-6.22 % |
4.68 % |
| II Quarter |
June |
- |
-24.63 % |
1.79 % |
7.75 % |
| I Quarter |
March |
-6.02 % |
-23.78 % |
1.28 % |
11.46 % |
| FY |
|
- |
-18.32 % |
-6.49 % |
6.88 % |
BIIB Revenue (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
-1.62 % |
-15.51 % |
1.98 % |
| III Quarter |
September |
- |
0.14 % |
-8.3 % |
-0.46 % |
| II Quarter |
June |
- |
3.01 % |
4.17 % |
3.64 % |
| I Quarter |
March |
-7.39 % |
-5.56 % |
-3.73 % |
-1.04 % |
| FY (Year on Year) |
|
- |
-18.32 % |
-6.49 % |
6.88 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 10.31 % |
2.41 % |
-7.19 % |
| (March 31, 2014) |
|
(Jun 30 2021) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 10.31 % |
2.41 % |
-7.19 % |
| (March 31, 2014) |
|
(Jun 30 2021) |
|
| Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Biogen Inc 's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
3.39 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's I. Quarter Q/Q Revenue Comment |
In the I. Quarter 2022 Biogen Inc realized drop in Revenue from the previous quarter by -7.39% to $ 2,531.80 millions, from $ 2,733.80 millions achived a quarter before.
When you analyse current shortcoming at the I. Quarter, you must presume, that usually I. Quarter 2022 results occur sluggish relative to the forth quarter
Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 627. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
3.39 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's I. Quarter Q/Q Revenue Comment |
In the I. Quarter 2022 Biogen Inc reported drop in Revenue from the previous quarter by -7.39% to $ 2,531.80 millions, from $ 2,733.80 millions achived in the previous reporting period.
This is not big concern, as Biogen Inc 's Revenue always seem to dip in the I. Quarter Chelsey Pereira, market contributor wrote.
Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 627. |
|
Biogen Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Mar 31 2022) |
12 Months Ending
(Dec 31 2021) |
12 Months Ending
(Sep 30 2021) |
12 Months Ending
(Jun 30 2021) |
12 Months Ending
(Mar 31 2021) |
| Cumulative Revenue 12 Months Ending |
$ 10,819.50 |
$ 10,981.70 |
$ 11,100.50 |
$ 11,697.70 |
$ 12,604.30 |
| Y / Y Revenue Growth (TTM) |
-14.16 % |
-18.32 % |
-22.17 % |
-19.26 % |
-12.61 % |
| Year on Year Revenue Growth Overall
Ranking |
# 818 |
# 401 |
# 123 |
# 151 |
# 2672 |
| Seqeuential Revenue Change (TTM) |
-1.48 % |
-1.07 % |
-5.11 % |
-7.19 % |
-6.25 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 766 |
# 2793 |
# 125 |
# 3566 |
# 3324 |
| Cumulative Revenue growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Revenue decline would be -14.16% year on year to $10,820 millions.
In the Healthcare sector 71 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 401 to 818. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
10.31 % |
2.41 % |
-7.19 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
10.95 % |
-22.17 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 9 |
| Sector |
# 76 |
| S&P 500 |
# 766 |
|
| Cumulative Revenue growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Revenue fall would be -14.16% year on year to $10,820 millions.
In the Healthcare sector 71 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 401 to 818. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
10.31 % |
2.41 % |
-7.19 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
10.95 % |
-22.17 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 9 |
| Sector |
# 76 |
| S&P 500 |
# 766 |
|
